The Panshengzi Public Welfare Initiative provides genetic testing services for 10,000 lung cancer patients

On December 13, the "Lung Love New Life" genetic testing public welfare project initiated by the China Primary Health Care Foundation was launched.

Chen Yixin, executive deputy secretary general of the China Primary Health Care Foundation, said, "The 'Lung Love New Life' gene testing public welfare project provides 10,000 cases of free testing for EGFR-negative non-small cell lung cancer patients, hoping that through the strength of the Initial Insurance Foundation and testing institutions, more people can enjoy the convenience of genetic testing, promote the standardization of lung cancer diagnosis and treatment, benefit more patients, and promote the development of accurate diagnosis and treatment." At the same time, I also hope that in the future, more enterprises that are as enthusiastic about public welfare as Panshengzi and are committed to improving the accessibility of precision medicine will join the public welfare projects and bring practical and effective medical diagnosis and treatment services to a wider range of people at the grassroots level. ”

Academician Yu Jinming of Shandong Provincial Cancer Hospital said that the "Lung Love New Life" public welfare project aims to provide more targeted treatment opportunities for patients with EGFR mutation-negative through NGS polygenic testing.

Professor Liu Dongge of Beijing Hospital also pointed out that a large number of studies have confirmed that for fusion genes, NGS detection technology has obvious advantages, among which RNA-related NGS detection methods are more accurate for the detection of fusion genes.

Professor Wang Jie of the Cancer Hospital of the Chinese Academy of Medical Sciences said that the accurate diagnosis and treatment of lung cancer is inseparable from the development of detection technology and its wide application in the clinic, and how to apply the detection technology to benefit the clinic is crucial for accurate diagnosis and treatment. The clinical efficacy and safety of NMPA-approved companion diagnostic products in combination with corresponding drugs have been fully verified, and the test results have clear clinical guiding significance.

Wang Sizhen, co-founder and CEO of Panshengzi, said, "Adhering to the mission of 'fighting cancer and protecting life', Panshengzi is committed to improving the accessibility of cancer precision medicine from three aspects: product service, technology research and development and concept popularization. In the future, we hope to work with more partners like the China Primary Health Care Foundation and AstraZeneca to provide more accessible services for Cancer Patients in China, so that more cancer patients can benefit from the integrated diagnosis and treatment model of genetic testing and medication services. At the same time, we will fully practice in social projects that promote service accessibility to meet the diversified clinical diagnosis and treatment needs of patients at all levels in China, bring tangible changes to patients, and provide technical support for building a healthy China. (Li Gongsheng)